Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$68.26 USD
-1.04 (-1.50%)
Updated May 17, 2024 03:59 PM ET
After-Market: $68.25 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RDY 68.26 -1.04(-1.50%)
Will RDY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDY
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Other News for RDY
Dr. Reddy’s Addresses USFDA Inspection Observations
Dr. Reddy’s Engages Investors in Upcoming Conferences
Dr. Reddy’s Labs GST Penalty Halved on Appeal
Dr. Reddy’s Marks 40 Years with Record Results
Barclays Sticks to Their Buy Rating for Dr Reddy’s Laboratories (RDY)